Skip to main content Skip to navigation

[University home]

School of Medicine

Professor Paul Durrington 

Photograph of Paul Durrington

Professor of Medicine

Cardiovascular Research Group
Core Technology Facility (3rd Floor)
46 Grafton Street
Manchester
M13 9NT

 

Role

Professor of Medicine

 

Research

Lipoproteins

Paul Durrington is the leader of the Lipoprotein Research Group. The group is recognised internationally for work that includes:

  • The discovery of inhibitory effect of insulin on the hepatic secretion of apolipoprotein B (apo B)-containing lipoproteins (‘bad cholesterol’)
  • The discovery of the role of paraoxonase located on high density lipoproteins (‘good cholesterol’) in protecting apo B-containing lipoproteins against changes leading to coronary heart disease (CHD)
  • The discovery that low paraoxonase activity is linked with diabetic microvascular complications.
  • The Collaborative Atorvastatin Diabetes Study (CARDS), showing for the first time that statin treatment is effective in the primary prevention of coronary heart disease and stroke in type 2 diabetes.

Recently we have investigated the importance of glycation on the atherogenicity of lipoproteins in dyslipidaemia, metabolic syndrome and diabetes and discovered that the highly atherogenic small dense subfraction of LDL is most susceptible to glycation and that its glycation can be impeded by HDL. In addition we have, with various national and international collaborators a commitment to the clinical investigation of monogenic disorders of lipoprotein and adipose tissue metabolism. These include studies using a national genetic register of patients with heterozygous familial hypercholesterolaemia and of methods to improve their detection. We also seek to discover the underlying causes of the lipodystrophies (disorders of adipose tissue distribution).

A randomised, clinical trial of a statin on the progression of renal disease in diabetes has recently commenced (with four NHS Trusts as partners) and our well-established translational research into the application of the results of cholesterol-lowering trials into clinical practice continues. In the latter context the University of Manchester holds the copyright for the Cardiovascular Risk Estimation Charts and computer programme used routinely in clinical practice in Britain.

Diabetes and obesity

Paul is a member of the Institute of Health Sciences Diabetes and Obesity Research Network. His research interests in this area include:

• Lipoprotein Metabolism
• Lipid Lowering Drugs
• Cardiovascular Disease Prevention
• Biochemical Basis of Atherosclerosis
• Insulin Resistance

 

Methodological Knowledge

  • Basic Sciences Methods
  • Clinical Trials
  • Cohort studies
  • Quantitative
  • Randomised control trials/experimental studies

I have had GCP/ICH training.

 

Teaching

Contributes regularly to undergraduate teaching and lectures frequently at postgraduate meetings. Former external examiner to Universities of Leeds and Sheffield and current member of the Examination Board of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians. Supervises PhD and MD students and has acted as a PhD examiner to British and overseas universities.

 

Biography

Paul Durrington trained in Physiology and Medicine in Bristol (BSc 1969; MBChB 1972; MRCP 1975; MD 1978), before moving to the University of Manchester in 1976 as a lecturer.

He visited the Division of Metabolic Medicine at University of California, San Diego as British Heart Foundation Travelling Fellow (1979-80). He was made a FRCP (London) in 1987, FRCPath in 1994, Fellow of the American Heart Association in 2001 and Fellow of the American College of Physicians in 2009. Paul is currently Honorary Professor of Medicine in the Cardiovascular Research Group in the School of Biomedicine and Consultant Physician at Manchester Royal Infirmary where he leads the Greater Manchester Vascular Research Network.

His research interests centre on disorders of lipoprotein metabolism, atherogenic modifications of lipoproteins, insulin resistance and diabetes. He was Chairman of the British Hyperlipidaemia Association from 1992 to 1995, a member of the British Heart Foundation Project Grants Committee from 1997 to 2000 and Director of Research and Development to the Central Manchester Healthcare Trust 1997-2001. Currently,a member of the European Science Foundation Genetics and Epidemiology of Atherosclerosis International Review Panel. In 2001 he was elected to the Fellowship of the Academy of Medical Sciences for his work on diabetic dyslipidaemia and on HDL metabolism. He is author of over 300 original papers and other publications.

 

Collaborators and affiliated staff

Collaborators
 

  • Professor HAW Neil, Oxford Centre for Diabetes, Endocrinology & Metabolism, Oxford
  • Professor Muriel Caslake, Dept of Pathological Biochemistry, Glasgow Royal Infirmary
  • Professor Allan D Sniderman, McGill Unit for the Prevention of Cardiovascular Disease Cardiology Division, Canada
  • Professor D John Betteridge, Dept of Medicine, The Middlesex Hospital
  • Professor David Wood, National Heart and Lung Institute, Charing Cross Hospital
  • Professor G Lowe, University of Glasgow (Glasgow Royal Infirmary)
  • Professor Graham A Hitman, Queen Mary's School of Medicine and Dentistry, University of London
  • Professor Helen Colhoun, Division of Community Health Sciences, University of Dundee
  • Professor John Fuller, Dept of Epidemiology and Public Health, UCH, London
  • Professor John JP Kastelein, Academic Medical Centre, The Netherlands
  • Professor Rob Hegele, Robarts Research Institute, ON Canada
  • Professor Steve Humphries, British Heart Foundation Laboratories, UCH, London
  • Dr IN Bruce. ARC Epidemiology Research Unit, University of Manchester
  • Dr Patrick McElduff, Datapharm, Australia
  • Professor Kennedy Cruickshank, Cardiovascular Research Group, University of Manchester
  • Dr Roberta Ara, ScHARR University of Sheffield
  • Dr Jeetesh Patel, Sandwell Medical Research Unit, Birmingham
  • Dr Robin Choudhury, Department of Cardiovascular Medicine, John Radcliffe Hospital, Oxford
  • Professor Stephen O'Rahilly, University of Cambridge Metabolic Research Laboratories, Addenbrooke's Hospital, Cambridge
  • Professor Chris Packard, Department of Pathological Biochemistry, Glasgow Royal Infirmary
 

Publications

2011

  • Ara R, Pandor A, Stevens J, Rafia R, Ward S, Rees A, Durrington P, Reynolds T, Wierzbicki A, Stevenson M. (2011). Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy? Eur J Cardiovasc Prev Rehabil, eScholarID:127716
  • Bansal N, Anderson SG, Vyas A, Gemmell I, Charlton-Menys V, Oldroyd J, Pemberton P, Durrington PN, Clayton PE, Cruickshank JK. (In-press). Adiponectin and Lipid Profiles Compared with Insulins in Relation to Early Growth of British South Asian and European Children: The Manchester Children's Growth and Vascular Health Study. J Clin Endocrinol Metab, eScholarID:127717
  • Colhoun HM, Betteridge DJ, Durrington P, Hitman G, Neil A, Livingstone S, Charlton-Menys V, Bao W, Demicco DA, Preston GM, Deshmukh H, Tan K, Fuller JH. (In-press). Total Soluble and Endogenous Secretory Receptor for Advanced Glycation Endproducts as Predictive Biomarkers of Coronary Heart Disease Risk in Patients With Type 2 Diabetes: An Analysis From the CARDS Trial. Diabetes, eScholarID:127718
  • Rutter MK, Prais HR, Charlton-Menys V, Gittins M, Roberts C, Davies RR, Moorhouse A, Jinadev P, France M, Wiles PG, Gibson JM, Dean J, Kalra PA, Cruickshank JK, Durrington PN. (2011). Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1). Diabetic Medicine, 28(1), 100-108. eScholarID:127715 | DOI:10.1111/j.1464-5491.2010.03139.x
  • Soran H, Durrington PN. (2011). Susceptibility of LDL and its subfractions to glycation. Curr Opin Lipidol, 22(4), 254-261. eScholarID:127719 | DOI:10.1097/MOL.0b013e328348a43f

2010

  • Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 376(9753), 1670-1681. eScholarID:127712 | DOI:10.1016/S0140-6736(10)61350-5
  • Huijgen R, Abbink EJ, Bruckert E, Stalenhoef AF, Imholz BP, Durrington PN, Trip MD, Eriksson M, Visseren FL, Schaefer JR, Kastelein JJ; Triple Study Group. (2010). Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial. Clin Ther, 32(4), 615-625. eScholarID:127710 | DOI:10.1016/j.clinthera.2010.04.014
  • Neil HA, Cooper J, Betteridge DJ, Capps N, McDowell IF, Durrington PN, Seed M, Mann JI, Humphries SE; Simon Broome Familial Hyperlipidaemia Register Group. (2010). All-cause and cardiovascular mortality in treated patients with severe hypertriglyceridaemia: A long-term prospective registry study. Atherosclerosis, 211(2), 618-623. eScholarID:127709 | DOI:10.1016/j.atherosclerosis.2010.03.006
  • Patel JV, Caslake MJ, Vyas A, Cruickshank JK, Prabhakaran D, Bhatnagar D, Reddy KS, Lip GY, Mackness MI, Hughes EA, Durrington PN. (2010). Triglycerides and small dense low density lipoprotein in the discrimination of coronary heart disease risk in South Asian populations. Atherosclerosis, 209(2), 579-584. eScholarID:127708 | DOI:10.1016/j.atherosclerosis.2009.10.010
  • Soran H, Charlton-Menys V, Hegele R, Wang J, Benbow EW, Roberts I, Wood G, Durrington P. (2010). Proteinuria and severe mixed dyslipidemia associated with a novel APOAV gene mutation. J Clin Lipidol, 4(4), 310-313. eScholarID:127713 | DOI:10.1016/j.jacl.2010.06.004
  • Younis NN, Soran H, Sharma R, Charlton-Menys V, Greenstein A, Elseweidy MM, Durrington PN. (2010). Small-dense LDL and LDL glycation in metabolic syndrome and in statin-treated and non-statin-treated type 2 diabetes. Diab Vasc Dis Res, 7(4), 289-295. eScholarID:127711 | DOI:10.1177/1479164110383063

2009

  • Brown L, Boyd O, Burden ST, Durrington PN. (2009). An investigation to determine the nutritional adequacy and individuals experience of a very low fat diet used to treat Type V hypertriglyce. Journal of Human Nutrition and Dietetics, 22(3), 232-238. eScholarID:1d19895 | DOI:10.1111/j.1365-277X.2009.00945.x
  • Charlton-Menys V, Betteridge DJ, Colhoun H, Fuller J, France M, Hitman GA, Livingstone SJ, Neil HA, Newman CB, Szarek M, DeMicco DA, Durrington PN. (2009). Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia, 52(2), 218-255. eScholarID:127699 | DOI:10.1007/s00125-008-1176-8
  • Charlton-Menys V, Betteridge DJ, Colhoun H, Fuller J, France M, Hitman GA, Livingstone SJ, Neil HA, Newman CB, Szarek M, DeMicco DA, Durrington PN. (2009). Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Clin Chem, 55(3), 473-480. eScholarID:127701 | DOI:10.1373/clinchem.2008.111401
  • Charlton-Menys, V, Betteridge, D, Colhoun, H, Fuller, J, France, MM, Hitman, G, Livingstone, S, Neil, H, Newman, C, Szarek, M, DeMicco, D, Durrington, PN. (2009). Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia, 52( 2), eScholarID:1d19739 | DOI:10.1007/s00125-008-1176-8
  • Charlton-Menys, V, Betteridge, D, Colhoun, H, Fuller, J, France, MM, Hitman, G, Livingstone, S, Neil, H, Newman, C, Szarek, M, DeMicco, D, Durrington, PN. (2009). Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Clin Chem, 55( 3), eScholarID:1d19735 | DOI:10.1373/clinchem.2008.111401
  • Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Charlton-Menys V, DeMicco DA, Fuller JH; CARDS Investigators. (2009). Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis, 54(5), 810-819. eScholarID:127706 | DOI:10.1053/j.ajkd.2009.03.022
  • Colhoun, H, Betteridge, D, Durrington, PN, Hitman, G, Neil, H, Livingstone, S, Charlton-Menys, V, Demicco, D, Fuller, J, NULL. (2009). Effects of Atorvastatin on Kidney Outcomes and Cardiovascular Disease in Patients With Diabetes: An Analysis From the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis, eScholarID:1d19734 | DOI:10.1053/j.ajkd.2009.03.022
  • Durrington PN. (2009). The first recorded heterozygote for familial hypercholesterolemia. J Clin Lipidol, 3(2), 146-148. eScholarID:127705 | DOI:10.1016/j.jacl.2009.02.002
  • Kwok S, Canoy D, Ashton WD, Lowe GD, Wood D, Humphries SE, Charlton-Menys V, Durrington PN. (2009). Increased C-reactive protein levels in overweight and obese women taking exogenous hormones: the United Kingdom Women's Heart Study (UKWHS). Clin Endocrinol (Oxf), 71(5), 727-732. eScholarID:127704 | DOI:10.1111/j.1365-2265.2009.03580.x
  • Lee JM, Robson MD, Yu LM, Shirodaria CC, Cunnington C, Kylintireas I, Digby JE, Bannister T, Handa A, Wiesmann F, Durrington PN, Channon KM, Neubauer S, Choudhury RP. (2009). Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol, 54(19), 1787-1794. eScholarID:127707 | DOI:10.1016/j.jacc.2009.06.036
  • Pandor A, Ara RM, Tumur I, Wilkinson AJ, Paisley S, Duenas A, Durrington PN, Chilcott J. (2009). Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med, 265(5), 568-580. eScholarID:127700 | DOI:10.1111/j.1365-2796.2008.02062.x
  • Semple RK, Sleigh A, Murgatroyd PR, Adams CA, Bluck L, Jackson S, Vottero A, Kanabar D, Charlton-Menys V, Durrington P, Soos MA, Carpenter TA, Lomas DJ, Cochran EK, Gorden P, O'Rahilly S, Savage DB. (2009). Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest, 119(2), 315-322. eScholarID:127703 | DOI:10.1172/JCI37432
  • Semple, R, Sleigh, A, Murgatroyd, P, Adams, C, Bluck, L, Jackson, S, Vottero, A, Kanabar, D, Charlton-Menys, V, Durrington, PN, Soos, M, Carpenter, T, Lomas, D, Cochran, E, Gorden, P, O'Rahilly, S, Savage, D. (2009). Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest, 119( 2), eScholarID:1d20112 | DOI:10.1172/JCI37432
  • Soran H, Younis N, Charlton-Menys V, Durrington PN. (2009). Variation in paraoxonase-1 activity and atherosclerosis. Curr Opin Lipidol, 20( 4), eScholarID:1d20111 | DOI:10.1097/MOL.0b013e32832ec141
  • Soran H, Younis NN, Charlton-Menys V, Durrington P. (2009). Variation in paraoxonase-1 activity and atherosclerosis. Curr Opin Lipidol, 20(4), 265-274. eScholarID:127728 | DOI:10.1097/MOL.0b013e32832ec141
  • Younis NNN, Charlton-Menys V, Sharma RR, Soran HH, Durrington PN. (2009). Glycation of LDL in non-diabetic people: Small dense LDL is preferentially glycated both in vivo and in vitro. Atherosclerosis, 202( 1), eScholarID:1d19749 | DOI:10.1016/j.atherosclerosis.2008.04.036

2008

  • Ara R, Pandor A, Tumur I, Paisley S, Duenas A, Williams R, Rees A, Wilkinson A, Durrington P, Chilcott J. (2008). Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model. Am J Cardiovasc Drugs, 8(6), 419-427. eScholarID:127702 | DOI:10.2165/0129784-200808060-00005
  • Ara R, Pandor A, Tumur I, Paisley S, Duenas A, Williams R, Wilkinson A, Durrington P, Chilcott J. (2008). Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries. Clinical Therapeutics, 30(8), 1508-1523. eScholarID:127696 | DOI:10.1016/j.clinthera.2008.08.002
  • Bhatnagar D, Soran HH, Durrington PN. (2008). Hypercholesterolaemia and its management. BMJ, 337, eScholarID:1d19743
  • Charlton-Menys V, Chobotova J, Durrington PN. (2008). Use of the TLX ultracentrifuge for the isolation of different density lipoproteins and effects of freeze/thawing of human plasma before ultracentrifugation. Clinical Chemistry and Laboratory Medicine, 46(9), 1285-1288. eScholarID:127691 | DOI:10.1515/CCLM.2008.254
  • Charlton-Menys V, Chobotova JJ, Durrington PN. (2008). Use of the TLX ultracentrifuge for the isolation of different density lipoproteins and effects of freeze/thawing of human plasma before ultracentrifugation. Clin Chem Lab Med, 46( 9), eScholarID:1d19747 | DOI:10.1515/CCLM.2008.254
  • Charlton-Menys V, Durrington PN. (2008). Human cholesterol metabolism and therapeutic molecules. Exp Physiol, 93( 1), eScholarID:1d19753 | DOI:10.1113/expphysiol.2007.035147
  • Cholesterol Treatment Trialists' (CTT) Collaborators. (2008). Efficacy of cholesterol lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet, 371, 117-125. eScholarID:127722 | DOI:10.1016/S0140-6736(08)60104-X
  • Durrington PN, Charlton-Menys V, Packard CJ, Caslake MJ, Wang J, Bhatnagar D, Scott J, Hegele RA. (2008). Familial hypobetalipoproteinemia due to a novel early stop mutation. J Clin Lipidol, 2(5), 384-390. eScholarID:127697 | DOI:10.1016/j.jacl.2008.08.446
  • Evans, C.E., Mylchreest, S., Charlton-Menys, V., Durrington, P. (2008). The role of hydrostatic pressure in foam cell formation upon exposure of macrophages to LDL and oxidised LDL. Atherosclerosis, 197(2), 596-601. eScholarID:127676 | DOI:10.1016/j.atherosclerosis.2007.08.027
  • Kwok S. McElduff P, Ashton DW, Lowe GDO, Wood D, Humphries SE, Charlton-Menys V, Durrington PN. (2008). Indices of obesity and cardiovascular risk factors in British Women. Obesity Facts, 1, 190-195. eScholarID:127721 | DOI:10.1159/000148778
  • Neil A, Cooper J, Betteridge J, Capps N, McDowell I, Durrington P, Seed M, Humphries SE. (2008). Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J, 29(21), 2625-2633. eScholarID:127698 | DOI:10.1093/eurheartj/ehn422
  • Neil HA, Perera R, Armitage JM, Farmer AJ, Mant D, Durrington PN. (2008). Estimated 10-year cardiovascular risk in a British population: results of a national screening project. Int J Clin Pract, 62(9), 1322-1331. eScholarID:127694 | DOI:10.1111/j.1742-1241.2008.01828.x
  • Newman CB, Szarek M, Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Demicco DA, Auster S, Fuller JH; Cards Investigators. (2008). The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS). Diab Vasc Dis Res, 5(3), 177-183. eScholarID:127692 | DOI:10.3132/dvdr.2008.029
  • Patel JV, Lim HS, Gunarathne A, Tracey I, Durrington PN, Hughes EA, Lip GY. (2008). Ethnic differences in myocardial infarction in patients with hypertension: effects of diabetes mellitus. Quarterly Journal of Medicine, 101(3), 231-236. eScholarID:127689 | DOI:10.1093/qjmed/hcm151
  • Soran H, Durrington P. (2008). Rosuvastatin: efficacy, safety and clinical effectiveness. Expert Opin Pharmacother, 9(12), 2145-2160. eScholarID:127693 | DOI:10.1517/14656566.9.12.2145
  • Weiner K, Durrington PN. (2008). Patients' understandings and experiences of familial hypercholesterolemia. Community Genet, 11(5), 273-282. eScholarID:127690 | DOI:10.1159/000121398
  • Younis N, Sharma R, Soran HH, Charlton-Menys V, Elseweidy M, Durrington PN. (2008). Glycation as an atherogenic modification of LDL. Curr Opin Lipidol, 19( 4), eScholarID:1d19745 | DOI:10.1097/MOL.0b013e328306a057

2007

  • Charlton-Menys V, Durrington PN. (2007). Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential. Drugs, 67( 1), eScholarID:1d19774
  • Charlton-Menys V, Liu YY, Moorhouse AAJ, Durrington PN. (2007). The robustness of the Roche 2nd generation homogenous HDL cholesterol (PEGME) method: assessment of the effect of serum sample storage for up to 8 years at -80 degrees C. Clin Chim Acta, 382( 1-2), eScholarID:1d19772 | DOI:10.1016/j.cca.2007.04.009
  • Charlton-Menys V, Pisciotta L, Durrington PN, Neary R, Short C, Calabresi L, Bartolini S. (2007). Molecular characterization of two patients with severe LCAT deficiency. eScholarID:1d16637
  • Charlton-Menys V, Pisciotta L, Durrington PN, Neary R, Short CC, Calabresi L, Calandra S, Bertolini S. (2007). Molecular characterization of two patients with severe LCAT deficiency. Nephrol Dial Transplant, 22( 8), eScholarID:1d19759 | DOI:10.1093/ndt/gfm311
  • Joy T, Cao H, Black GCM, Malik RA, Charlton-Menys V, Hegele R, Durrington PN. (2007). Alstrom syndrome (OMIM 203800): a case report and literature review. Orphanet J Rare Dis, 2, eScholarID:1d19754 | DOI:10.1186/1750-1172-2-49
  • Povey A.C, Jury F, Dippnall M, Smith T, Thomson S, Mackness B, Durrington PN, Cherry N.M, Mackness MI. (2007). GST, CYP and PON1 polymorphisms in farmers attributing ill-health to organophosphate containing sheep-dip. 12, 288-202. eScholarID:1d16632
  • Raikou, M, McGuire, A, Colhoun, H, Betteridge, D, Durrington, PN, Hitman, G, Neil, H, Livingstone, S, Charlton-Menys, V, Fuller, J, NULL. (2007). Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia, 50( 4), eScholarID:1d19773 | DOI:10.1007/s00125-006-0561-4

2006

  • Charlton-Menys V, Liu YY, Durrington PN. (2006). A semi-automated method for the determination of serum paraoxonase activity using paraoxon as substrate. Clinical Chemistry, 52, 453-457. eScholarID:1d27048 | DOI:10.1373/clinchem.2005.063412
  • Gemmell IM, Heller RF, Payne K, Edwards R, Roland M, Durrington PN. (2006). The potential population impact of the UK Government strategy for reducing the burden of coronary heart disease in England: comparing primary and secondary prevention strategies. Quality and Safety in Health Care, eScholarID:1d27484
  • Hegele RA, Cao H, Liu DM, Costain GA, Charlton-Menys V, Rodger NW, Durrington PN. (2006). Sequencing of the re-annotated LMNB2 gene reveals novel mutations in patients with acquired partial lipodystrophy. American Journal Of Human Genetics, 79, 383-389. eScholarID:1d27485 | DOI:10.1086/505885
  • Humphries, SE, Whittall, RA, Hubbert, CS, Maplebeck, S, Cooper, JA, Soutar, A, Naoumova, R, Thompson, GR, Seed, M, Durrington, PN, Miller, PJ P, Betteridge, DJ, Neil, HA. (2006). Genetic causes of familiar hypercholesterolaemia in UK patients: relation to plasma lipid levels and coronary heart disease risk. Journal Of Medical Genetics, eScholarID:1d27492
  • Kovacs, TJ, Harris, S, Vas, TK, Seres, I, Short, CD, Wittmann, IK, Paragh, G, Mackness, MI, Mackness, B, Durrington, PN, Nagy, JM, Brenchley, PEC. (2006). Paraoxonase gene polymorphism and serum activity in progressive IgA nephropathy. Journal of Nephrology, 19, 732-738. eScholarID:1d27752
  • Patel JV, Vyas A, Cruickshank (K, Prabhakaran D, Hughes E, Reddy KS, Mackness MI, Bhatnagar D, Durrington PN. (2006). Impact of migration on coronary heart disease risk factors: comparison of Gujaratis in Britain and their contemporaries in villages of origin in India. Atherosclerosis, 185 (2), 297-306. eScholarID:1d26508 | DOI:10.1016/j.atherosclerosis.2005.06.005

2005

  • Charlton-Menys V, Durrington PN. (2005). Apolipoprotein A5 and hypertriglyceridemia. Clin Chem, 51( 2), eScholarID:1d19789 | DOI:10.1373/clinchem.2004.044826
  • Gemmell IM, Heller RF, McElduff P, Payne K, Butler G, Edwards R, Roland M, Durrington PN. (2005). The population impact of stricter adherence to recommendations for pharmacological and lifestyle interventions over one year in patients with coronary heart disease. Journal Of Epidemiology And Community Health, 59, eScholarID:1d26697
  • Heald, A, Anderson, S, Vyas, A, Siddals, KW, Patel, J, Yates AP, Bhatnagar, D, Prabhakaran D, Hughes, E, Rudenski, A, Durrington, PN, Gibson, JM, Cruickshank, (K. (2005). Marked differences in the IGF-system associated with migration in comparable populations of Gujaratis living in Sandwell UK and Gujarat India. Diabetologia, 48(9), eScholarID:1d26504
  • Mishra M, Durrington PN, Mackness M, Siddals KW, Kaushal K, Davies R, Gibson JM, Ray DW. (2005). Atorvastatin affects the serum lipoprotein profile and cardiovascular risk in acromegaly. Clin Endocrinol (Oxf), 62, 650-655. eScholarID:1d19275 | DOI:10.1111/j.1365-2265.2005.02273.x
  • Patel, JV, Vyas, A, Prabhakaran, D, Bhatnagar, D, Durrington, PN, Heald, A, Hughes, E, Mackness, MI, Reddy, KS, Cruickshank, (K. (2005). Non-esterified fatty acids as mediators of glucose intolerance in Indian Asian populations. Diabetes Care, 28, 1505-1507. eScholarID:1d26512

2004

  • Colhoun H, Betteridge DJ, Durrington, PN, Hitman GA, Neil HAW, Livingstone SJ, Thomason MJ, Mackness, MI, Charlton-Menys, V, Fuller JH, CARDS investigators. (2004). Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): a multicentre randomised placebo-controlled trial. Lancet, 364, 685-969. eScholarID:1d26009 | DOI:10.1016/S0140-6736(04)16895-5
  • El-Magadmi M, Bodill H, Ahmad Y, Durrington PN, Mackness MI, Walker MG, Bernstein RR, Bruce IN. (2004). Systemic lupus erythematosus. An independent risk factor for endothelial dysfunction in women. Circulation, 110, 399-404. eScholarID:1d26007
  • Hooper, L, Thompson, R, Harrison, RA, Summerbell, C, Moore, H, Worthington, H, Durrington, PN, Ness, A, Capps, N, Davey, S, Riemersma, R, Ebrahim, S. (2004). Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst Rev, ( 4), eScholarID:1d8991

2002

  • Cherry N, Mackness MI, Durrington PN, Povey AC, Dippnall WM, Smith T, Mackness B. (2002). Paraoxonase (PON1) polymorphisms in farmers attributing ill health to sheep dip. Lancet, 359, 763-764. eScholarID:1d23863

1990

  • BN Patel, Mackness MI, DW Harty, S Arrol, Boot-Handford RR, Durrington PN. (1990). Serum esterase activities and hyperlipidaemia in the streptozotocin- diabetic rat. Biochim. Biophys. Acta, 1035, 113-116. eScholarID:1d33453
  • Patel B, Mackness M, Harty D, Arrol S, Boot-Handford RR, Durrington PN. (1990). Serum esterase activities and hyperlipidaemia in the streptozotocin-diabetic rat. Biochim Biophys Acta, 1035( 1), 113-6. eScholarID:1d19483

Top of page

| Skip to main content | Skip to navigation | Skip to Search |